Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company usually posts poor financials for mid or long term investments.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 63.39, which offers good timing for buyers.
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The underlying tendency is negative on the weekly chart below the resistance at 77.45 EUR
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
SANOFI-8.41%102 299
JOHNSON & JOHNSON-6.57%342 627
PFIZER0.30%217 064
NOVARTIS-4.37%213 465
ROCHE HOLDING LTD.-12.15%193 887
MERCK AND COMPANY4.71%158 813
AMGEN0.56%117 021
ABBOTT LABORATORIES4.78%103 942
BAYER-3.56%102 645
GLAXOSMITHKLINE7.49%100 124
NOVO NORDISK A/S-12.38%95 622
ASTRAZENECA-3.06%89 830
ELI LILLY AND COMPANY-5.38%87 110
BRISTOL-MYERS SQUIBB COMPAN..-14.52%85 512
CELGENE CORPORATION-12.71%68 456
ALLERGAN PLC1.99%57 246
More Results
Financials (€)
Sales 2018 35 059 M
EBIT 2018 8 624 M
Net income 2018 4 942 M
Debt 2018 14 584 M
Yield 2018 4,67%
P/E ratio 2018 16,19
P/E ratio 2019 14,33
EV / Sales 2018 2,77x
EV / Sales 2019 2,60x
Capitalization 82 663 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart SANOFI
Duration : Period : Day
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Duration : Period : Week
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders